Expert Review of Neurotherapeutics , December 2012, Vol. 12, No. 12, Pages 1481-1481. mehr
Um alle Funktionen dieser Seite zu nutzen, aktivieren Sie bitte die Cookies in Ihrem Browser.
my.bionity.com
Mit einem my.bionity.com-Account haben Sie immer alles im Überblick - und können sich Ihre eigene Website und Ihren individuellen Newsletter konfigurieren.
Subsidized access to medical and pharmacy benefits is not a goal in and of itself; it is a means toward an end (improved health outcomes). Accordingly, the addition of an outpatient prescription drug benefit (Part D) to Medicare in 2006 will be deemed a success if it provides better, more affordable access to outpatient prescription drugs for Medicare beneficiaries and, more importantly, improves drug adherence and health outcomes, together with reducing or at least bending the cost curve by offsetting certain healthcare costs such as hospitalizations and emergency room visits. Priest and colleagues examine these claims and find suboptimal outcomes despite improved access.
| Autoren: | Joshua P Cohen | |
| Journal: | Expert Review of Pharmacoeconomics & Outcomes Research | |
| Jahrgang: | 2012 | |
| DOI: | 10.1586/erp.12.25 | |
| Erscheinungsdatum: | 19.07.2012 |
Merkliste
Hier setzen Sie die nebenstehende Fachpublikation auf Ihre persönliche Merkliste.
Zusatzinformationen
Expert Review of Neurotherapeutics , December 2012, Vol. 12, No. 12, Pages 1481-1481. mehr
Is DaTSCAN really needed for accurate Parkinson’s disease diagnosis?
Expert Review of Neurotherapeutics , December 2012, Vol. 12, No. 12, Pages 1375-1377. mehr
New concepts in the early and preclinical detection of Parkinson’s disease: therapeutic implications
Parkinson’s disease is a chronic neurodegenerative disorder leading to progressive motor impairment for which there is no cure. Currently, the diagnosis is made by the presence of cardinal motor features and several associated non-motor symptoms. However, at this point, the underlying neuro ... mehr